Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

Details

• Alternative Title:
  Vaccine
• Personal Author:
  Osorio, Jorge E. ; Huang, Claire Y.-H. ; Kinney, Richard M. ; Stinchcomb, Dan T.
• Description:
  Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.
• Subjects:
  Animals Clinical Trials, Phase I As Topic Dengue Dengue Vaccines Dengue Virus Humans Models, Animal Vaccines, Attenuated Vaccines, Synthetic
• Keywords:
  DEN-2 PDK-53 Virus Dengue Fever Dengue Virus Recombinant Viral Vaccine Vaccine Development
• Source:
  Vaccine. 29(42):7251-7260
• Pubmed ID:
  21777638
• Pubmed Central ID:
  PMC4592106
• Document Type:
  Journal Article
• Funding:
  CC999999/Intramural CDC HHSUnited States/
• Volume:
  29
• Issue:
  42
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:8d153813725c20e285128c190163883aa37753453632dc91d5c8a9ddda39fdc92c8aef98379619d30dfc955ebee272a1bad38d66ff1bbcca55cef9c46c2b004e
• Download URL:
  https://stacks.cdc.gov/view/cdc/34673/cdc_34673_DS1.pdf
• File Type:
  [PDF - 513.75 KB ]